ADVI Research: Impact of the COVID-19 Pandemic on Healthcare Utilization Among Medicare Beneficiaries with CVD

Strategic Analytics, Value and Economics

May 25, 2024

ADVI Health Strategic Analytics, Value and Economics (SAVEs) data analyst, David Liu, and the team presented four poster presentations at ISPOR 2024. One of the studies analyzed the impact of the COVID-19 pandemic on healthcare utilization among Medicare beneficiaries with cardiovascular disease (CVD).

This research study had two primary objectives.

First, to assess how the pandemic influenced healthcare services, such as inpatient care, emergency room visits, hospital outpatient visits, and physician office consultations.

Secondly, understand the long-term effects of the pandemic on healthcare utilization trends for CVD patients. The team analyzed data from 22 million CVD patients using 100% Medicare Fee-for-Service (FFS) data from 2018 to 2023.

The analysis revealed significant reductions in healthcare services during the pandemic. The expected average hospital inpatient rate was predicted to be around 50 per 10,000 beneficiaries per month between April and July 2020. However, during the pandemic, the observed average inpatient visit rate dropped to 32 per 10,000 beneficiaries.

Outpatient and physician office services experienced a 4.5 percent decrease in visit rate per 10,000 beneficiaries during the pandemic. Inpatient service use saw a minor reduction post-pandemic by 0.7 percent. Skilled nursing facility services showed a 1.8 percent decrease post-pandemic, although the drop during the pandemic was non-significant.

These findings indicate that the pandemic has led to lasting changes in healthcare utilization among cardiovascular disease patients in the Medicare population.

Moving forward, healthcare systems must recognize and address these changes to ensure ongoing and enhanced care for CVD patients.

Learn More

ADVI experts will continue analyzing Medicare data trends to deepen our understanding of the pandemic’s impact on healthcare utilization and to help develop effective strategies for improving patient care. Get in touch today to gain expert insights on the evolving healthcare landscape.


CEO insights

Real analysis from people who’ve been there

RAND/UCLA Modified Delphi Panels

ADVI Health partners with pharmaceutical and biotech organizations to advance their evidence generation and market access strategies. We support complex research questions through primary research (e.g., …

Caitlin Sheetz, MPH
June 23, 2026

Cell and Gene Precision Medicine State Policy

The 2026 Rare Disease Reality

Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …

Marc Samuels, JD, MPH
February 26, 2026

Uncategorized

How HEOR and Real-World Evidence Are Reshaping Decisions in 2026

By 2026, health economics and outcomes research (HEOR) and real-world evidence (RWE) will look less like a supporting function and …

February 10, 2026

Precision Medicine

2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption

In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …

Marc Samuels, JD, MPH
December 16, 2025

Inflation Reduction Act

Real-World Effectiveness vs Clinical Trial Efficacy in Medicare

The Inflation Reduction Act (IRA) has ushered in a new era of drug pricing negotiations in the US. For the …

October 1, 2025

Inflation Reduction Act Pharmaceuticals and Biotech

Why is Medicare Data Central to IRA Negotiations?

The Inflation Reduction Act (IRA), passed in 2022, has transformed the way drug pricing will be managed in the United …

September 10, 2025

Pharmaceuticals and Biotech

PHAR Partners Present at the National Bleeding Disorders Conference

Jonathan James, patient and patient advocate for a hemophilia advocacy group, partnered with PHAR (Partnership for Health Analytic Research) and …

September 16, 2024

ADVI Angle Vertical

Cell and Gene

ADVI Research: Medicare Beneficiaries with Multiple Administrations of CAR-T

ADVI Health Strategic Analytics, Value and Economics (SAVEs) chief data scientist, Pete Kardel, and the team presented four poster presentations …

Peter Kardel, MA
May 21, 2024

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.